<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and three patients suffering from <z:hpo ids='HP_0004850'>recurrent venous thrombosis</z:hpo>, recurrent arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and/or recurrent <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and 50 healthy subjects were tested for Hageman factor (FXII) coagulant activity and antigen </plain></SENT>
<SENT sid="1" pm="."><plain>Among the 103 patients we identified 15 subjects with FXII deficiency (15%), 3 with <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> (3%) and 3 with <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> (3%) </plain></SENT>
<SENT sid="2" pm="."><plain>Combined FXII and protein C, protein S or <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> was not observed </plain></SENT>
<SENT sid="3" pm="."><plain>The 103 patients were divided into subgroups according to the type of thrombotic complication </plain></SENT>
<SENT sid="4" pm="."><plain>Among patients with exclusively recurrent venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> 8% (p = 0.153) were deficient in FXII </plain></SENT>
<SENT sid="5" pm="."><plain>Among patients suffering from recurrent arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and/or <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, the incidence of FXII deficiency was significantly higher (20%, p less than 0.003) </plain></SENT>
<SENT sid="6" pm="."><plain>In 67% of the patients with FXII deficiency a positive family history of <z:mp ids='MP_0005048'>thrombosis</z:mp> could be established </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, only 32% of <z:hpo ids='HP_0000001'>all</z:hpo> venous and 28% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> patients had a positive family history </plain></SENT>
<SENT sid="8" pm="."><plain>We believe that reduced levels of FXII should be considered as a risk factor in the development of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Consequently, more attention should be payed to the measurement of FXII when evaluating thromboembolic risk factors especially in cases of recurrent arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and/or <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
</text></document>